Apparatus New Drug For IDH1 Mutation/Relapsed/Refractory Acute Myeloid Leukaemia With Good Complete Remission Rates And Manageable Toxicity Jun 20, 2025 Jun 20, 2025 The results of a new study recently showed that Olutasidenib monotherapy in patients with relapsed/refractory acute myeloid leukaemia carrying the IDH1 mutation elicited high rates of complete remission with manageable toxicity.
